Cleerly will use the funds to invest in additional large-scale outcomes research to validate its artificial intelligence (AI) technology for evaluating coronary CT angiograms to allow physicians to identify, characterize, and qualify atherosclerosis in the walls of the heart arteries more easily.

Cleerly has more than a dozen ongoing clinical trials, including an international registry enrolling more than 100,000 patients over the next decade.